Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2025 Dec;22(12):944-960.
doi: 10.1038/s41569-025-01150-1. Epub 2025 Apr 14.

Post-translational acylation of proteins in cardiac hypertrophy

Affiliations
Review

Post-translational acylation of proteins in cardiac hypertrophy

Ying-Qi Liu et al. Nat Rev Cardiol. 2025 Dec.

Abstract

Acylations are post-translational modifications in which functional groups are attached to amino acids on proteins. Most acylations (acetylation, butyrylation, crotonylation, lactylation, malonylation, propionylation and succinylation) involve lysine but cysteine (palmitoylation) and glycine (myristoylation) residues can also be altered. Acylations have important roles in physiological and pathophysiological processes, including cardiac hypertrophy and related cardiovascular diseases. These post-translational modifications influence chromatin architecture, transcriptional regulation and metabolic pathways, thereby affecting cardiomyocyte function and pathology. The dynamic interaction between these acylations and their regulatory enzymes, such as histone acetyltransferases, histone deacetylases and sirtuins, underscores the complexity of cellular homeostasis and pathological processes. Emerging evidence highlights the therapeutic potential of targeting acylations to modulate enzyme activity and metabolite levels, offering promising avenues for novel treatments. In this Review, we explore the diverse mechanisms through which acylations contribute to cardiac hypertrophy, highlighting the complexity and potential therapeutic targets in this regulatory network.

PubMed Disclaimer

Conflict of interest statement

Competing interests: The authors declare no competing interests.

References

    1. Roth, G. A. et al. Global burden of cardiovascular diseases and risk factors, 1990-2019: update from the GBD 2019 study. J. Am. Coll. Cardiol. 76, 2982–3021 (2020). - PubMed - PMC - DOI
    1. Roger, V. L. Epidemiology of heart failure: a contemporary perspective. Circ. Res. 128, 1421–1434 (2021). - PubMed - DOI
    1. Heymans, S., Lakdawala, N. K., Tschöpe, C. & Klingel, K. Dilated cardiomyopathy: causes, mechanisms, and current and future treatment approaches. Lancet 402, 998–1011 (2023). - PubMed - DOI
    1. Zhu, L., Li, C., Liu, Q., Xu, W. & Zhou, X. Molecular biomarkers in cardiac hypertrophy. J. Cell. Mol. Med. 23, 1671–1677 (2019). - PubMed - PMC - DOI
    1. Grossman, W. Cardiac hypertrophy: useful adaptation or pathologic process? Am. J. Med. 69, 576–584 (1980). - PubMed - DOI

LinkOut - more resources